LaserSight sells subsidiaries for $13 million:
This article was originally published in Clinica
Executive Summary
LaserSight has sold two of its health service subsidiaries, MEC Health Care and LSI Acquisition, to the eye care practice management company Vision Twenty-One for $13 million. Half the price will be paid in cash at closing and half in common stock, said LaserSight. The US company is working on the LSX platform for refractive surgery and said it would use $3.5 million of the net proceeds to repay loans.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.